# Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma

> **NCT07699939** · PHASE2 · RECRUITING · sponsor: **National Cancer Center, Japan** · enrollment: 136 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** serplulimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07699939
- **Lead sponsor:** National Cancer Center, Japan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2028-11-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07699939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07699939, "Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma". Retrieved via MORVS 2026-10-31 from https://api.morvs.ai/clinical/NCT07699939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*